China, India and Japan lead the pharmaceutical market in Asia

Source: Biovalley 2015-03-18 predicts that by 2019, India and Japan, the two leading pharmaceutical markets in Asia, will grow by 11% and 8%, respectively, while China will achieve a record of 12% this year alone According to the limited information reported by various research institutions recently, China's overall pharmaceutical market, India's API Market and Japan's generic pharmaceutical market will become the three leading leaders of the Asian pharmaceutical market According to a report related to the Chinese pharmaceutical market, the Chinese pharmaceutical market will increase to US $110.26 billion this year, while the overall medical industry is expected to grow by 13.5% Apart from the mainland market, another report on Hong Kong estimates that its pharmaceutical market will reach US $1.7 billion this year, an increase of 8.5%, while the medical market will grow by 7% According to the long-term tracking report on the Indian and Japanese markets, from 2014 to 2019, India expects to achieve a compound annual growth rate of 10.76% through the API market After a short transition period this year, the pharmaceutical market in India as a whole will grow healthily, the report said Japan's generic market forecast is slightly conservative, with a compound annual growth rate of only 8.16% from this year to 2019 At the same time, the market share will be divided by six leading companies, namely Meiji Seika Pharma, Nichi IKO, NIPRO Pharma, Sawai, Teva and towa According to other reports, Japan's overall pharmaceutical market growth is also not optimistic It is expected to reach US $79.8 billion by 2020, with a compound annual growth rate of only 1.8% Although the Japanese government calls for generic drugs to replace brand drugs, the percentage of development driven by new drugs (generic drugs) is very small The report also predicts that with the expansion of universal coverage, Japan's medical device market will grow by 6.1% to US $75 billion in 2020